TY - JOUR
T1 - Non-coding RNA therapeutics in cardiovascular diseases and risk factors
T2 - Systematic review
AU - Ardiana, Meity
AU - Fadila, Asiyah Nurul
AU - Zuhra, Zakirah
AU - Kusuma, Nabilla Merdika
AU - Surya Erlangga Rurus, Made Edgard
AU - Oceandy, Delvac
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/12
Y1 - 2023/12
N2 - At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.
AB - At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.
KW - Cardiogenetics
KW - Cardiovascular diseases
KW - Cardiovascular risk factors
KW - Non-coding RNA
KW - RNA therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85164279999&partnerID=8YFLogxK
U2 - 10.1016/j.ncrna.2023.06.002
DO - 10.1016/j.ncrna.2023.06.002
M3 - Review article
AN - SCOPUS:85164279999
SN - 2468-0540
VL - 8
SP - 487
EP - 506
JO - Non-coding RNA Research
JF - Non-coding RNA Research
IS - 4
ER -
